Prot# NU 02H8 (PCYC-0213): A Phase I/II Trial of Redox Regulation in Patients with Relapsed or Refractory CD20 Positive Non-Hodgkin's Lymphoma (NHL): Combining 90Yttrium-Zevalin & Redox-Modulating Agent, Motexafin Gadolinium (MGd)

Project: Research project

Project Details

StatusFinished
Effective start/end date7/23/039/1/11

Funding

  • Pharmacyclics, Inc. (NU 02H8 (PCYC-0213))